ALZAMEND NEURO INC (ALZN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.66-2.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALZN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue raising capital via equity sales including Series D convertible preferred stock and ATM offerings to support operations.
Stated as a priority in 2 of last 2 quarters. The company executed a Securities Purchase Agreement for up to 25,000 shares of Series D convertible preferred stock in 2026-Q4 and an ATM sales agreement for up to $3 million of common stock in 2026-Q1. These capital raising activities align with management's stated focus on securing funding to support operations, indicating delivery on this priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Entered into Securities Purchase Agreement for Series D convertible preferred stock.”
“Entered into ATM Issuance Sales Agreement to sell up to $3 million of common stock.”
Resolve Nasdaq listing rule non-compliance related to independent board majority and stockholders' equity to maintain listing status.
Stated as a priority in 2 of last 2 quarters. The company disclosed Nasdaq notices regarding failure to meet the majority independent board standard and stockholders' equity requirements in 2026-Q1 and 2026-Q4. These regulatory challenges remain unresolved, indicating ongoing focus but limited progress on compliance.
“Notified Nasdaq of non-compliance with majority independent board standard.”
“Received Nasdaq letter regarding stockholders' equity non-compliance and potential delisting.”
Control operating losses and negative cash flow from operations while advancing clinical and corporate activities.
Stated as a priority in all 8 quarters from 2025-Q1 through 2026-Q4. Operating losses increased from approximately $962K in 2025-Q1 to $2.87M in 2026-Q4, while negative cash from operations rose from $688K in 2025-Q4 to $2.8M in 2026-Q4. This indicates ongoing operating losses and cash burn with a worsening trajectory, reflecting limited progress in cost containment.
“Operating loss of $2.87M and negative cash from operations of $2.8M.”
“Operating loss of $2.2M and negative cash from operations of $1.7M.”
“Operating loss of $998K and negative cash from operations of $1.17M.”
“Operating loss of $2.7M and negative cash from operations of $2.36M.”
“Operating loss of $1.14M and negative cash from operations of $688K.”
“Operating loss of $1.04M and negative cash from operations of $1.42M.”
“Operating loss of $1.36M and negative cash from operations of $3.4M.”
“Operating loss of $962K and negative cash from operations of $1.05M.”
Over the trailing year it converted 1.36x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.